Maze Therapeutics (NASDAQ:MAZE) CEO Sells $103,818.00 in Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CEO Jason Coloma sold 3,993 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $26.00, for a total value of $103,818.00. Following the sale, the chief executive officer directly owned 25,930 shares of the company’s stock, valued at approximately $674,180. This represents a 13.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Maze Therapeutics Trading Up 5.2%

Shares of MAZE stock opened at $28.43 on Friday. The company has a market capitalization of $1.57 billion, a P/E ratio of -11.24 and a beta of 2.26. The company has a current ratio of 17.88, a quick ratio of 17.88 and a debt-to-equity ratio of 0.11. The business’s 50 day moving average is $25.68 and its two-hundred day moving average is $35.98. Maze Therapeutics, Inc. has a twelve month low of $10.98 and a twelve month high of $53.65.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.02). The firm had revenue of $20.00 million during the quarter. Equities analysts forecast that Maze Therapeutics, Inc. will post -2.73 EPS for the current year.

Institutional Investors Weigh In On Maze Therapeutics

Institutional investors have recently made changes to their positions in the stock. Royal Bank of Canada increased its holdings in shares of Maze Therapeutics by 128.3% in the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock valued at $27,000 after purchasing an additional 363 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in Maze Therapeutics during the fourth quarter worth about $39,000. Ameritas Investment Partners Inc. boosted its holdings in Maze Therapeutics by 82.6% during the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after buying an additional 738 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in Maze Therapeutics during the fourth quarter worth about $43,000. Finally, Russell Investments Group Ltd. grew its position in Maze Therapeutics by 947.8% during the third quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock worth $49,000 after buying an additional 1,725 shares during the period.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on MAZE. HC Wainwright raised their target price on shares of Maze Therapeutics from $60.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, March 25th. Wedbush increased their price target on shares of Maze Therapeutics from $43.00 to $58.00 and gave the stock an “outperform” rating in a report on Monday, March 16th. BTIG Research restated a “buy” rating and issued a $46.00 price objective on shares of Maze Therapeutics in a research report on Wednesday, March 25th. JPMorgan Chase & Co. lifted their price objective on Maze Therapeutics from $52.00 to $58.00 and gave the company an “overweight” rating in a report on Tuesday, March 31st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $66.00.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.